On 15 October 2014, orphan designation (EU/3/14/1352) was granted by the European Commission to GlaxoSmithKline Trading Services Limited, Ireland, for raxibacumab for the treatment of inhalation anthrax disease.
The sponsorship was transferred to Emergent Countermeasures International Ltd., United Kingdom, in January 2018.
The sponsorship was transferred to Emergent Netherlands B.V., The Netherlands, in April 2019.
|Disease / condition||
Treatment of inhalation anthrax disease
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;